November 2009
Clinical Trial Results of the successful phase 2b study on the HypoMon® were presented at 9th Annual Diabetes Technology Meeting, San Francisco November 5-7, 2009.

December 2008
AiMedics report Clinical Trial Results

AiMedics recently completed a successful phase 2b study on its non-invasive hypoglycaemia detection device, the HypoMon®. This relatively large study enrolled 52 Type 1 Diabetic sufferers over 3 months in a controlled overnight comparative study. The results suggest that HypoMon’s non-invasive technology has excellent market potential in that it matches the hypoglycaemia alarm performance of the best of the continuous monitoring devices in this field.

November 2008
Officially granted US patent US7,450,986.

November 2008
Nearing completion of Clinical Trials with Princess Margaret Hospital.

June 2007
LIFE-SAVING DIABETES INVENTION FAST-TRACKED BY GOVERNMENT
Sydney-based AiMedics has won a major Federal Government grant to fast-track the development of a unique non-invasive device that alerts insulin-dependent diabetics of life-threatening hypoglycaemia (low blood-sugar levels).

AiMedics Chairman, Martin Greenberg, said today that the Federal Department of Industry had granted the company up to $2.755 Million to accelerate the commercial development of its HypoMon® product to assist the growing number of insulin-dependent diabetics in Australia and around the world.

Hypoglycaemia can lead to coma, seizures or death, unless it is detected early enough and counteracted with a ‘sugar’-based product such as orange juice or intravenous glucose.

AiMedics CEO, Victor Skladnev, said the Commonwealth funding would complement the significant investment in HypoMon® already committed by GBS Venture Partners.

“We are very pleased with the ‘commercial-ready’ grant which will help us to get our valuable and potentially life-saving device on the market and available to those suffering from insulin-dependent diabetes,” Mr Skladnev said.

Australian Industry Minister, Ian Macfarlane, said HypoMon® was a great example of how Australian innovation is helping to deliver real health benefits to people with chronic illnesses.

"Diabetes is one of Australia's fastest growing chronic diseases and improving the detection of low blood sugar levels will greatly enhance the health outcome of patients," Mr Macfarlane said.

"The Australian government's Commercial Ready grant will ensure the potentially life-saving device is commercialised and in the hands of those who need it as soon as possible."

May 2007
Expansion of staff including the appointment of a R&D Engineer(Fransesco La Tella), Mathematician(Bernadette Le Mesurier) and a Senior Devices Scientist (Dr. Stan Tarnavskii).

April 2007
AiMedics commences the overnight Stage II (Glucose - freefall) clinical studies of the HypoMon® for Type1 diabetic children at the Princess Margaret Hospital for children (PMH) in Perth.

November 2006
Expansion of staff including the appointment of a CEO (Victor Skladnev), Senior Electronics Engineer (Theo Masselos) and a Software Engineer (Raymond Sinn).

November 2006
The conclusion of the HypoMon® children pre-clinical studies were presented at the 6th Annual Diabetes Technology Meeting, Atlanta 2006.

October 2006
AiMedics commences the overnight Stage I (Glucose - clamp) clinical studies of the HypoMon® for Type1 diabetic children at the Princess Margaret Hospital for children (PMH) in Perth.

September 2006
AiMedics has securred venture capital funding of $4.5 million through GBS Venture Partners and the initial AiMedics investors. GBS (GBS Ventures) is one of Australia’s leading life sciences venture capital groups and has had considerable success in building companies based on Australian technology. The new funding from GBS will be used to further the development of HypoMon®.

June 2006
The results of the HypoMon® paediatric pre-clinical studies were presented at the 66th Annual American Diabetes Association (ADA) Conference, Washington DC 2006.

January 2006
AiMedics concludes the pre-clinical studies of the HypoMon® both at the Prince of Wales Hospital (Adult population) and at the Princess Margaret Hospital (Children population).

page: Next

Webmaster: admin@aimedics.com
© AiMedics 2009 | Disclaimer